Is Takeda Pharmaceutical Co Ltd (TAK) Stock About to Get Hot Friday?

Takeda Pharmaceutical Co Ltd (TAK) stock has fallen 7.91% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Takeda Pharmaceutical Co Ltd has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TAK!

See Full TAK Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With TAK Stock Today?

Takeda Pharmaceutical Co Ltd (TAK) stock is unchanged 0% while the S&P 500 is higher by 0.32% as of 4:00 PM on Thursday, Oct 26. TAK is flat $0.00 from the previous closing price of $13.38 on volume of 691,572 shares. Over the past year the S&P 500 is higher by 8.35% while TAK is higher by 3.16%. TAK earned $0.41 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 33.29. To see InvestorsObserver's Sentiment Score for Takeda Pharmaceutical Co Ltd click here.

More About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Click Here to get the full Stock Report for Takeda Pharmaceutical Co Ltd stock.